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ABSTRACT
The human DNA repair protein O
6-methylguanine
DNA methyltransferase (MGMT) dealkylates muta-
genic O
6-alkylguanine lesions within DNA in an
irreversible reaction which results in inactivation of
the protein. MGMT also provides resistance of
tumours to alkylating agents used in cancer chemo-
therapy and its inactivation is therefore of particular
clinical importance. We describe a post-DNA syn-
thesis strategy which exploits the novel, modified
base 2-amino-6-methylsulfonylpurine and allows
access for the first time to a wide variety of
oligodeoxyribonucleotides (ODNs) containing O
6-
alkylguanines. One such ODN containing O
6-(4-
bromothenyl)guanine is the most potent inactivator
described to date with an IC50 of 0.1 nM.
INTRODUCTION
The catalytic properties of certain DNA repair proteins can be
investigated using chemically synthesized oligodeoxyribo-
nucleotide (ODN) substrates. This has previously required
the production of phosphoramidites containing appropriately
protected bases in order to generate ODNs of deﬁned sequence
and containing single, or multiple, lesions of known structure.
That each putative substrate requires the synthesis of a speciﬁc
phosphoramidite has inhibited comprehensive studies in
this area: the majority of work is undertaken using a very
limited number of commercially available precursors. One
DNA repair protein for which the availability of a wide variety
of ODN substrates would be of considerable beneﬁt is
O
6-methylguanine-DNA methyltransferase (MGMT) (1).
MGMT protects normal cells against the toxic and mutagenic
effects of endogenous and environmental alkylating agents by
repairing toxic O
6-alkylguanine lesions in DNA which can
otherwise mispair with thymine during replication (2). Repair
involves the transfer of the alkyl group to the active site
cysteine in a stoichiometric direct damage reversal pathway
in which MGMT is inactivated (3). MGMT also protects
tumour cells against the action of chemotherapeutic alkylating
agents such as temozolomide and BCNU (carmustine).
This has generated interest in compounds that inactivate
MGMT and thereby sensitize tumour cells to killing by
these agents (4,5). Substrates of MGMT are O
6-alkylguanines
of extremely diverse structure (6–16). To study the repair of
O
6-alkylguanine-containing DNA, the use of a single phos-
phoramidite that allows the efﬁcient post-synthesis modiﬁca-
tion of ODNs to produce such deﬁned lesions was considered a
potential advance. We have therefore established a protocol
based on a methylsulfonyl leaving group that provides a facile
and efﬁcient route to a wide variety of potential MGMT
substrates that hitherto were unavailable using existing post-
DNA synthesis chemistries. Here we present the synthesis
and post-DNA modiﬁcation of ODNs containing the
20-deoxyribonucleoside of 2-amino-6-methylsulfonylpurine.
We generate examples of ODNs containing biologically
relevant guanine residues and characterize their interaction
with human MGMT.
We chose O
6-methylguanine (O
6-MeG) and O
6-(2-
hydroxyethyl)guanine (O
6-HOEtG) (Figure 1) because they
are generated in DNA by environmental carcinogens and
certain cancer chemotherapeutic agents (17). We also
examined O
6-benzylguanine (O
6-BnG) (18,19) and O
6-(4-
bromothenyl)guanine [O
6-(4-BTG)] because, as free bases,
they are currently in clinical trials (18–20) as MGMT
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doi:10.1093/nar/gkl117inactivating agents (see above). In this context we show that
a novel 16mer ODN containing O
6-(4-bromothenyl)guanine
displays a picomolar IC50 value against human MGMT which
is lower than any inactivator of the protein tested to date.
MATERIALS AND METHODS
Chemical synthesis
6-Thio-20-deoxyguanosine (1). According to method described
by Kung and Jones (21), sodium hydrosulﬁde hydrate (16.2 g,
289 mmol) was placed in a round bottom ﬂask and ﬂame-dried
with Bunsen burner until no more water was evolved. The
remaining orange solid was cooled to room temperature
under vacuum, and dry DMF (180 ml) was added to the
ﬂask under an Ar atmosphere. The ﬂask was placed in a son-
icator and the solid crushed by sonication overnight. The
majority of sodium hydrosulﬁde dissolved to give a dark
green solution. 20-Deoxyguanosine monohydrate (1.5 g, 5.3
mmol) was dried by evaporation of dry pyridine (3 · 30 ml),
suspended in dry pyridine (120 ml) under Ar and cooled in an
ice bath. To this was added dropwise triﬂuoroacetic anhydride
(7.0 ml, 49.6 mmol) and the mixture was stirred for 1 h to
afford a dark orange solution. To this was added the sodium
hydrosulﬁde DMF solution in portions whilst the mixture was
stirred at 0 C under Ar. The ice bath was removed and the
mixture then stirred overnight at room temperature. The reac-
tion mixture was then poured into saturated aqueous ammo-
nium bicarbonate solution (300 ml), stirred for 6 h, the solvent
removed under reduced pressure and the residual oil evapor-
ated at 80 C under vacuum. To the remaining solid was added
methanol (300 ml) and the white powder which formed was
removed by ﬁltration. The ﬁltrate was evaporated to a solid,
and 0.1 M triethylammonium acetate added. A black ﬁne
precipitate which formed was removed by ﬁltration, the ﬁltrate
evaporated, and the residue recrystallized from methanol/
water ¼ 50/50 (100 ml) to give 1 (1.5 g, quantitative) as a
light purple-coloured powder. Analytical data were identical
to that described elsewhere (21).
9-[30,5 0- Bis(tert-butyldimethylsilyl)-20-deoxyribofuranosyl]-
2-amino-6-methylsulfanylpurine (2). To a solution of 6-thio-
20-deoxyguanosine (2.4 g, 8.47 mmol) in concentrated
aqueous ammonia (20 ml) was added iodomethane (1.0 ml,
16.1 mmol), and the mixture stirred for 1 h. The solvent was
removed under reduced pressure, the residue dried under
vacuum, then by coevaporation with dry pyridine (2 ·
30 ml). The residue was dissolved in dry DMF (20 ml),
and stirred with imidazole (5.8 g, 85.2 mmol) and tert-
butyldimethylchlorosilane (3.8 g, 25.2 mmol) for 3 h at
room temperature. The reaction mixture was concentrated
and diluted with ethyl acetate (100 ml). The organic layer
was washed with water (50 ml) and brine (50 ml), dried
(Na2SO4) and evaporated. Puriﬁcation by silica column
chromatography (hexane/EtOAc ¼ 4/1 to 3/1) afforded 2 as
a white foam (3.9 g, 88%). Rf(hexane/EtOAc¼3/1) ¼ 0.50;
1H
NMR (CDCl3, d): 7.91 (1H, s, H8), 6.34–6.29 (1H, m, H10),
4.92 (2H, bs, NH2), 4.60–4.55 (1H, m, H30), 4.00–3.96 (1H,
m, H40), 3.83–3.71 (2H, m, H50), 2.63 (3H, s, MeS),
2.63–2.53 (1H, m, H20), 2.39–2.30 (1H, m, H20), 0.91
(9H, s), 0.90 (9H, s), 0.10 (6H, s), 0.074 (3H, s), 0.069
(3H, s); ES
+MS (m/z): 526.2704 ([M+H]
+, calc. for
C23H44N5O3Si2S ¼ 526.2703).
9-[30,5 0- Bis(tert-butyldimethylsilyl)-20-deoxyribofuranosyl]-
2-amino-6-methylsulfonylpurine (3). To a solution of 2
(2.0 g, 3.80 mmol) in ethanol/water (2:1, 60 ml) was added
magnesium monoperphthalate solution in water (80%, 5.2 g,
8.41 mmol in 20 ml) dropwise at room temperature, and the
mixture stirred for 3 h. The solvent was removed under
reduced pressure, and EtOAc (100 ml) and saturated aqueous
sodium bicarbonate (30 ml) were added to the residue. The
organic layer was separated, washed sequentially with water
(20 ml) and brine (20 ml), dried (Na2SO4) and evaporated.
Puriﬁcation by silica column chromatography (hexane/
EtOAc ¼ 1/4) gave 3 as a white foam (1.3 g, 61%). Rf
(hexane/EtOAc ¼ 1/4) ¼ 0.24;
1H NMR (CDCl3, d): 8.24
(1H, s, H8), 6.36 (1H, t, J ¼ 6.6 Hz, H10), 5.50 (2H, bs,
NH2), 4.60–4.55 (1H, m, H30), 4.03–3.99 (1H, m, H40),
3.82 (1H, dd, J ¼ 3.7, 11.0 Hz, H50), 3.75 (1H, dd,
J ¼ 3.7, 11.0 Hz, H50), 3.42 (3H, s, MeSO2), 2.60–2.50
(1H, m, H20), 2.39 (1H, ddd, J ¼ 3.7, 6.0, 13.0 Hz, H20),
0.91 (9H, s), 0.89 (9H, s), 0.10 (6H, s), 0.079 (3H, s),
0.073 (3H, s); ES
+MS (m/z): 558.2599 ([M+H]
+, calc. for
C23H44N5O5Si2S ¼ 558.2602).
9-[30,5 0-O-Bis(tert-butyldimethylsilyl)-20-deoxyribofuranosyl]-
N
2-[(dimethylamino)methylidene]-2-amino-6-methylsulfo-
nylpurine (4). Compound 3 (1.3 g, 2.12 mmol) was dissolved
in freshly distilled methanol (10 ml), activated 3 s molecular
sieves were added and the mixture stirred for 30 min under Ar.
N, N-Dimethylformamide dimethylacetal (2.3 ml, 17.3 mmol)
was then added, the mixture stirred overnight, then ﬁltered
through celite and evaporated. The residue was puriﬁed by
silica column chromatography (CHCl3/MeOH ¼ 99/1) to give
4 as a white foam (866 mg, 61%). Rf (CHCl3/MeOH¼98/2) ¼
0.50;
1H NMR (CDCl3, d): 8.79 (1H, s, amidine), 8.41 (1H, s,
H8), 6.63 (1H, t, J ¼ 6.4 Hz, H10), 4.56–4.51 (1H, m, H30),
4.00–3.97 (1H, m, H40), 3.85 (1H, dd, J ¼ 3.2, 11.1 Hz, H50),
3.76 (1H, dd, J ¼ 3.2, 11.1 Hz, H50), 3.46 (3H, s, MeSO2),
3.20 (3H, s, –NMe2), 3.19 (3H, s, –NMe2), 2.49–2.32 (2H, m,
H20), 0.90 (9H, s), 0.89 (9H, s), 0.093 (3H, s), 0.090 (3H, s),
0.07 (6H, s); ES
+MS (m/z): 613.3042 ([M+H]
+, calc. for
C26H49N6O5Si2S ¼ 613.3024).
Figure 1. O
6-Alkylguanine lesions in DNA; O
6-methylguanine (O
6-MeG)
and O
6-(2-hydroxyethyl)guanine (O
6-HOEtG) and potent inactivators of
human MGMT; O
6-benzylguanine(O
6-BnG) and O
6-(4-bromothenyl)guanine
[O
6-(4-BTG)].
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2-[(dimethylamino)methylidene]-
2-amino-6-methylsulfonylpurine (5). To a solution of com-
pound 4 (4.2 g, 6.85 mmol) in anhydrous THF (40 ml) was
added triethylamine trihydroﬂuoride (2.5 ml, 15.3 mmol)
and the mixture stirred overnight at room temperature under
Ar. The reaction mixture was then diluted with dichloro-
methane (100 ml) and the precipitate formed was collected
by ﬁltration and washed with dichloromethane (100 ml) to
give 5 as a white powder (2.1 g, 80%). This product was
used for the next reaction without further puriﬁcation.
Rf (CHCl3/MeOH ¼ 4/1) ¼ 0.50;
1HN M R( d6-DMSO, d):
8.75 (1H, s, amidine), 8.72 (1H, s, H8), 6.47 (1H, t, J ¼ 6.7 Hz,
H10), 5.41 (1H, d, J ¼ 4.3 Hz, 30-OH), 5.06 (1H, t, J ¼ 5.5 Hz,
50-OH),4.49–4.44 (1H, m, H30), 3.94–3.90 (1H, m, H40),
3.68–3.55 (2H, m, H50), 3.55 (3H, s, MeSO2), 3.23 (3H, s,
–NMe2), 3.11 (3H, s, –NMe2), 2.80–2.70 (1H, m, H20),
2.42–2.33 (1H, m, H20); ES
+MS (m/z): 385.1311 ([M+H]
+,
calc. for C14H21N6O5S ¼ 385.1294).
9-(50-O-Dimethoxytrityl-20-deoxyribofuranosyl)-N
2-[(dimethyl-
amino)methylidene]-2-amino-6-methylsulfonylpurine (6). To
a solution of 5 (1.9 g, 2.49 mmol) in dry DMF (50 ml) was
added diisopropylethylamine (1.3 ml, 7.46 mmol) and dimeth-
oxytrityl chloride (2.0 g, 5.90 mmol). The reaction mixture
was stirred under Ar for 4 h at room temperature. Methanol
(2 ml) was then added and the solvent evaporated. The residue
was dissolved in ethyl acetate (100 ml) and washed sequen-
tially with saturated aqueous sodium bicarbonate (25 ml),
water (25 ml) and brine (25 ml). The organic layer was
dried (Na2SO4), ﬁltered and evaporated and the residue puri-
ﬁedbysilicacolumnchromatography(CHCl3with1%Et3Nto
CHCl3/MeOH ¼ 97/3 with 1% Et3N) to give 6 as a white foam
(3.1 g, 91 %). Rf (CHCl3/MeOH ¼ 97/3) ¼ 0.15;
1HN M R
(CDCl3, d) ¼ 8.76 (1H, s, amidine), 8.22 (1H, s, H8),
7.40–7.16 (9H, m, DMTr), 6.82–6.76 (4H, m, DMTr), 6.61
(1H, t, J ¼ 6.4 Hz, H10), 4.63–4.58 (1H, m, H30), 4.15–4.10
(1H, m, H40), 3.77 (6H, s, 2· MeO), 3.44 (3H, s, MeSO2),
3.38 (2H, t, J ¼ 4.0 Hz, H50), 3.18 (3H, s, –NMe2), 3.17 (3H, s,
–NMe2), 2.59 (2H, t, J ¼ 5.8 Hz, H20); ES
+MS (m/z)
¼ 687.2582 ([M+H]
+, calc. for C35H39N6O7S ¼ 687.2601).
9-(50-O-Dimethoxytrityl-20-deoxyribofuranosyl)-N
2-[(dimethyl-
amino)methylidene]-2-amino-6-methylsulfonylpurine 30-
(2-cyanoethyl-N,N-diisopropyl)-phosphoramidite (7). To a
solution of 6 (385 mg, 0.56 mmol) in anhydrous dichloro-
methane (10 ml) was added diisopropylethylamine (390 ml,
2.24 mmol) under an Ar atmosphere and the mixture cooled in
an ice bath. 2-Cyanoethyl-N,N-diisopropyl chlorophosphor-
amidite (250 ml, 1.12 mmol) was then added dropwise and
the reaction stirred for 30 min at 0 C, then for 2 h at room
temperature. The reaction mixture was diluted with EtOAc
(50 ml) and washed sequentially with saturated aqueous
sodium bicarbonate (10 ml), water (10 ml) and brine (10 ml).
The organic layer was dried (Na2SO4), ﬁltered and evaporated
and the residue puriﬁed by column chromatography (hexane/
acetone ¼ 2/1 to hexane/acetone ¼ 1/1 to CHCl3/acetone ¼
4/1 to CHCl3/acetone ¼ 2/1 to CHCl3/MeOH ¼ 98/2, all
eluents contained 1% Et3N) to give 7 as a white foam
(293 mg, 59%). Rf (hexane/acetone ¼ 1/1) ¼ 0.33;
1H
NMR (CDCl3, d) ¼ 8.79 (1H, s, amidine), 8.26 (1H, d,
J ¼ 11.0 Hz, H8), 7.41–7.18 (9H, m, DMTr), 6.82–6.77
(4H, m, DMTr), 6.64 (1H, t, J ¼ 6.7 Hz, H10), 4.70–4.63
(1H, m, H30), 4.27–4.23 (1H, m, H40), 3.88–3.30 (6H, m,
OCH2CH2CN and H50), 3.771 (3H, s, MeO), 3.768 (3H, s,
MeO), 3.45 (3H, s, MeSO2), 3.20 (3H, s, –NMe2), 3.19 (3H, s,
–NMe2), 2.66–2.57 (3H, m, [(Me2CH)N]2 and H20), 2.43 (1H,
t, J ¼ 6.9 Hz, H20), 1.28–1.05 (12H, m, [(Me2CH)N]2);
31P NMR (CDCl3, d) ¼ 149.18; ES
+MS (m/z) ¼ 887.3710
([M+H]
+, calc. for C44H56N8O8PS ¼ 887.3679).
Oligodeoxyribonucleotide synthesis
ODNs were synthesised using standard protocols on an
Applied Biosystems 394 automated synthesiser using mild/
fast deprotection phosphoramidites, reagents and columns
(acetyl dC, t-butylphenoxyacetyl dG and dA). All syntheses
were performed on a 1 mmol scale using 0.1 M solutions
of normal phosphoramidites and a 0.15 M solutions of the
modiﬁed phosphoramidite 7. Following DNA synthesis, the
CPG-bound protected ODN (approximately one-third of
sample) was treated with 500 ml of alcohol/dry acetonitrile/
dry DBU (9:9:2, v/v/v) and incubated at 37 C for 2 days.
Concentrated aqueous ammonia solution (33%, 1 ml) was
then added and the mixture shaken for 3 days at room tem-
perature. For water insoluble alcohols (4-bromothenyl, benzyl
and DMTrOCH2CH2OH), the aqueous layer was removed
with a pipette and the organic layer extracted with 500 ml
of water and the water layers combined. The ODN solutions
were then concentrated to residual oils ( 100 ml) and CH2Cl2
(1 ml) added. The suspension was then brieﬂy vortexed, cent-
rifuged and the liquid decanted leaving an ODN pellet. The
pellet was dissolved in water (500 ml) and puriﬁed by reversed
phase high-performance liquid chromatography (HPLC)
(Hichrom ACE C18 4.6 · 250 mm column) using the follow-
ing conditions: buffer A ¼ 5% CH3CN in 0.1 M aqueous
triethylammonium bicarbonate pH 7.0, buffer B ¼ CH3CN,
linear gradient of 0–20% B over 30 min, ﬂow rate 1 ml/min,
monitored at260 nm.Typicalretention times forthe ODNs are
shown in Table 1. Following HPLC puriﬁcation, samples were
evaporated and redissolved in water (500 ml) puriﬁed using
a spin column (MILLIPORE Microcon  3000 molecular
weight cut off) and characterized by MALDI ms (Table 1).
(The hydroxyethyl-modiﬁed ODN was detritylated with 20%
aqueous acetic acid for 30 min then evaporated and redis-
solved in water prior to spin column puriﬁcation). Following
analysis, ODN solutions were evaporated and stored as
100 mM solutions in dry dimethyl sulfoxide at  20 C.
Determined extinction coefﬁcients at 260 nm for the modiﬁed
bases in water at pH 7 were as follows; 3.4 for O
6-
methylguanine and O
6-hydroxyethylguanine, 3.6 for O
6-
benzylguanine and 5.5 for O
6-(bromothenyl)guanine. These
Table 1. Physical data of 16mer ODNs (50-AACAGCCATATXGCCC)
Modification (X) HPLC
a retention
time (min)
MALDI ms data
Calculated Found
G 23.4 4835.1 4836
O
6-MeG 24.9 4849.2 4851
O
6-BnG 25.9 4925.3 4927
O
6-hoEtG 23.1 4881.2 4881
O
6-(4-BTG) 27.0 5010.2 5011
aHPLC conditions are described in Materials and Methods.
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the modiﬁed ODNs as described elsewhere (22).
MGMT assays
Recombinant human MGMT was overexpressed in E.coli
strain UC978 which is deleted for the endogenous alkyltran-
ferases ada and ogt (23) Cell-free extracts were prepared by
sonication in buffer I (50 mM Tris–HCl, 1 mM EDTA and
3 mM DTT, pH 8.3) containing phenylmethlysulfonyl ﬂuoride
and leupeptin, and centrifugation at 4 C for 10 min in a refri-
gerated microcentrifuge. The amounts of MGMT present in
thecrudesonicatesweredeterminedfollowingincubationwith
N-nitroso-N-[
3H]methylurea-methylated calf thymus substrate
DNA for 60 min at 37 C as described elsewhere (24). To
assess the ability of the ODNs to inactivate MGMT, aliquots
(88 fmol) of MGMT were incubated in buffer I (50 mM
Tris–HCl, 1 mM EDTA and 3 mM DTT, pH 8.3) with incre-
mentally increasing amounts of ODNs at 37 C for 60 min.
Excess [
3H]-methylurea-methylated calf thymus substrate
DNA was then added and incubation continued for a further
hour, and samples processed as described. A pilot experiment
was ﬁrstly carried out using a very wide range of concentra-
tions to establish the range to use for each ODN. IC50 values
were determined from the lines of best ﬁt to the dose-response
curves (Figure 3) and represent the amount of inactivator
required to reduce the MGMT activity to 50%. The data
used in the dose–response curves were the mean of triplicate
measurements. To ensure that the pre-incubation had been
carried out for sufﬁcient time for the initial reaction to go
to completion, ﬁxed amounts of ODNs that did not achieve
complete inactivation of MGMT in the titration assay were
incubated with 88 fmol of MGMT at 37 C for various times
up to 4 h then processed as above.
RESULTS AND DISCUSSION
The post-synthetic modiﬁcation of DNA involves the incorp-
oration of a reactive nucleoside analogue into the synthetic
oligomer via an appropriate phosphoramidite precursor
(25–30). The reactive nucleoside contains a suitable leaving
group at the desired position on its heterocyclic base which
may be displaced by nucleophiles following DNA synthesis.
The analogue must display a complete stability to the reagents
employed in the coupling cycle during standard DNA syn-
thesis but possess a sufﬁciently high reactivity to allow the
subsequentefﬁcient andselectivetransformationtothedesired
modiﬁed derivative.
Post-DNA/RNA synthesis chemistry that has been
employed successfully for the preparation of oligonucleotides
containing 6-modiﬁed purine nucleosides has utilized
leaving groups such as phenoxide (23,26) and methyl-
sulfoxide, methylsulfonyl and chloride (27,29,30). However,
none of these examples afford DNA containing a 2-amino-
6-substituted purine and in all cases, the leaving group of the
modiﬁed base is displaced by an efﬁcient nucleophile such
as a thiol or an amine. The preparation of DNA containing
O
6-alkylguanines using post-DNA synthesis is considerably
more challenging due to the much lower electrophilicity
at C6 of 6-substituted derivatives of 2-aminopurine versus
analogous 6-substituted purines. Previously, DNA containing
2-amino-6-modiﬁed purines (26) has been prepared via
post-DNA synthesis using ODNs containing S
6-(2,4-
dinitrophenyl)thioguanine (30). However, this chemistry has
only been used for the preparation of O
6-methylguanine-con-
taining DNA, which involves displacement of the thiolate
leaving group by methanol, i.e. a relatively nucleophilic
alcohol (26). Furthermore, the 2,4-dinitrophenylthio group
is not ideal in this context since it has two electrophilic
sites and thus can also undergo nucleophilic addition to the
2,4-dinitrobenzene moiety leading to the formation of thio-
guanine (26,27). Of interest to us was the need for DNA
containing O
6-modiﬁed guanines bearing alkyl groups
more complex than methyl that are not accessible by these
existing methods. O
6-Sulfonate esters have been employed
previously to prepare O
6-alkylguanine (13) and O
6-alkyl-20-
deoxyguanosine analogues (31) using a two-step process that
involves the initial displacement of the leaving group by a
tertiary amine, which in turn is displaced by an alcohol. How-
ever, we expected that these derivatives would be too reactive
for use during DNA synthesis (32) and as an alternative we
considered the use of either 6-sulfoxy- or preferably the more
reactive 6-sulfonyl-2-aminopurine-containing ODNs. Based
on the known trends in leaving group ability during nucleo-
philic aromatic substitution reactions (SNAr) reactions (33),
we expected such analogues to display a reactivity inter-
mediate between that of the analogous sulfonate esters
and the 2,4-dinitrothiophenol derivative described by
Xu (27). Although the 20-deoxyribonucleoside of 2-amino-
6-methylsulfonylpurine has not been prepared previously,
the high reactivityof6-methylsulfonylpurine20-deoxyriboside
(34) and of oligonucleotides containing 6-methylsulfo-
nylpurine (29,30) has been described elsewhere. Thus we
envisaged a post-DNA synthesis strategy in which DNA con-
taining 2-amino-6-methylthiopurine-20-deoxyriboside could
be oxidized using MMPP to the corresponding sulfone.
Previously DNA (29) containing 6-methylsulfoxypurine and
RNA (30) containing 6-methylsulfonylpurine has been
obtained following MMPP oxidation of a synthetic ODN
containing 6-methylthiopurine. Thus, initially we prepared
a 12mer ODN containing 2-amino-6-methylthiopurine using
the phenoxyacetyl-protected phosphoramidite monomer
described previously (8). Following DNA synthesis, the modi-
ﬁed ODN was then treated with two equivalents of MMPP.
Oxidation to the corresponding sulfoxide occurred cleanly
within 3 h [as evidenced by HPLC (Supplementary Figure 1)
and characterization of a new M+16 peak by MALDI ms].
However, the corresponding sulfone-modiﬁed DNA was not
formed even after prolonged treatment with excess MMPP
(50 equiv., 1 week) (data not shown). Furthermore, displace-
ment of the methylsulfoxy group within the modiﬁed ODN by
alcohols was extremely inefﬁcient (data not shown).
As an alternative we considered that the sulfone-modiﬁed
base could be incorporated into DNA directly using an
appropriately protected phosphoramidite. Consequently we
prepared the novel sulfone phosphoramidite 7 in six steps
from 20-deoxythioguanosine (Scheme 1). Initially 20-deoxy-
thioguanosine was alkylated using MeI under basic conditions
and then protected on the 30 and 50 hydroxyl groups using
TBDMSCl and the product 2 puriﬁed by silica column chro-
matography. In principle, the protection of the sugar of the
modiﬁed nucleoside is not required during the synthesis of 7.
Nucleic Acids Research, 2006, Vol. 34, No. 6 1887However, in practise we have found large variability in the
purity of 20-deoxythioguanosine that has been prepared from
20-deoxyguanosine using the described one-pot procedure
(which employs triﬂuoroacetic anhydride and NaSH) (21).
The protection of the 20-deoxythioguanosine following
methylation provides a compound which is readily puriﬁed
by silica column chromatography and as a consequence
even relatively impure samples of the thionucleoside can be
used in the synthesis. The oxidation of compound 2 to give the
sulfone 3 was achieved using MMPP. Deprotection of N
2-
isobutyryl-O
6-alkylguanine-containing ODNs under standard
conditions (NH4OH, 55 C for 6 h) can lead to the formation
of 2,6-diaminopurine and guanine-containing DNA (35).
However, such problems can be eliminated when the pheno-
xyacetyl protecting group is used since this can be removed
under milder conditions (NH4OH, room temperature) (8). For
this reason we chose the dimethylformamidine moiety for pro-
tection of the amino group of 7 since it can also be removed
under mild conditions but in addition, it is easy to introduce.
For reasons outlined above, we chose to prepare a 16mer
ODN containing the four different O
6-alkylguanine modiﬁ-
cations indicated. The ODN sequence chosen is shown
in Scheme 2. This sequence containing O
6-benzylguanine
is known to be an excellent substrate for MGMT (36). The
synthesis of the modiﬁed ODNs was performed using the
modiﬁed phosphoramidite 7 together with base-labile phos-
phoramidite reagents of the standard nucleosides (acetyl C,
t-butylphenoxyacetyl G and A) and with ﬁnal removal of the
50-dimethoxytrityl protecting group. The phosphoramidite 7
was used in a standard coupling protocol but was employed
as a 0.15 M solution in acetonitrile rather than the normal
0.1 M concentration and gave comparable coupling efﬁcien-
cies to the normal phosphoramidites. Following synthesis, the
CPG-bound ODN was treated with the desired alcohol
together with DBU dissolved in dry acetonitrile (alcohol: acet-
onitrile: DBU, 9:9:2 v/v/v) for 2 days (Scheme 2). Aqueous
ammonia solution was then added and after 3 days the ODNs
were puriﬁed by reversed phase HPLC and characterized by
MALDI ms (Table 1). All ODNs displayed masses within 4
mass units of their calculated masses. A typical HPLC trace
before puriﬁcation is shown in Figure 2 for the ODN contain-
ing O
6-benzylguanine.
The conditions used by Xu et al. (26) for the post-DNA
synthesis of O
6-methylguanine-containing DNA involve the
displacement of a 2,4-dinitrophenylthio leaving group using a
mixture containing alcohol/DBU 9:1. However in our hands,
this produced highly viscous solutions when an alcohol other
than methanol was used. Furthermore, following ammonia
Scheme 1. Synthesis of sulfone phosphoramidite. Reagents and conditions: (i) NH4OH, MeI then TBDMSCl, imidazole, DMF, 88%; (ii) MMPP, aqueous EtOH,
61%;(iii)N,N-dimethylformamidedimethylacetal,DMF,61%;(iv)Et3N.HF,DMF,80%;(v)DMTrCl,pyridine,91%;(vi)i-Pr2NP(Cl)OCH2CH2CN,(i-Pr2N)2EtN,
CH2Cl2, 59%.
Scheme 2. Post-DNA synthesis modification of ODNs to incorporate O
6-alkylguanine analogues (R ¼ methyl, benzyl, 4-bromothenyl, DMTrOCH2CH2–).
1888 Nucleic Acids Research, 2006, Vol. 34, No. 6deprotection of the DNA, ODNs containing guanine rather
than the O
6-alkylguanine analogue were obtained. The high
reactivity of the methylsufonyl group toward nucleophilic dis-
placement by alcohol/DBU was conﬁrmed by using
1H NMR.
Thus in a model experiment, we monitored the time required
for completion of the displacement reaction using deuterated
methanol as the nucleophile (Supplementary Figure 2).
Thus, whilst the reaction was complete in 10 mins at room
temperature for 2-amino-6-methylsulfonylpurine-20-deoxy-
riboside, the analogous reaction with S
6-(2,4-dinitrophenyl)-
thio-20-deoxyguanosine required over 2 h. These results
clearly demonstrate the much higher reactivity of the methyl-
sulfonyl leaving group toward displacement by alcohols and
our approach provides a practical and convenient procedure
for the generation DNA containing O
6-alkylguanines. It is
interesting to note the very large disparity in reactivity of
the 2-amino-6-methylsulfonylpurine in the nucleoside and
the ODN, the latter requiring 2 days for complete reactivity.
The very large difference in reactivity between substituted
purines in nucleosides and within DNA has also been noted
byothers(30).This differenceinreactivityunderlines the need
for a very good leaving group at the 6-position of the purine in
order to prepare a wide variety of O
6-alkylguanines using
post-DNA synthesis.
The ability of the modiﬁed ODNs to act as inactivators of
human MGMT was assessed using a standard assay (24) in
which the ODNs were preincubated with the protein for 1 hour
followed by the addition of an excess of DNA containing
tritiated O
6-methylguanine. Residual MGMT activity remain-
ing after the preincubation step is measured by the incorpora-
tion of the tritium label. To establish that the period of
incubation of the ODNs with MGMT was appropriate for
the reaction to proceed to completion, amounts of the
ODNs that gave measurable, but not complete inactivation
of MGMT were incubated for various times with MGMT
prior to addition of radiolabelled substrate DNA as described
elsewhere (24). Under these conditions the inactivation
of MGMT by the ODN substrates was complete within
30 min at 37 C (data not shown). The results indicate that
the O
6-MeG-, O
6-BnG- and O
6-(4-BTG)-, but not the
hydroxyethyl guanine-modiﬁed ODNs, were effective inactiv-
ators of MGMT. The IC50 values for these ODNs were derived
from dose-response curves (Figure 3) and represent the con-
centration of inactivator required to reduce the activity of
MGMT by 50%. The respective IC50 values are displayed
in Table 2. Under the conditions used, the O
6-BnG- and
O
6-(4-BTG)-containing ODNs were  900 and 34 times
more effective than the free bases (37). Furthermore, these
Table 2. IC50values of ODNs and free base inactivators of human MGMT
Human MGMT inactivator IC50 (mM)
d(AAC AGC CAT AT(O
6-MeG) GCC C) 0.0157
d(AAC AGC CAT AT(O
6-BnG) GCC C) 0.0002
d(AAC AGC CAT AT[O
6-(4-BTG)] GCC C) 0.0001
d(AAC AGC CAT AT(O
6-HOEtG) GCC C) 5.50
O
6-methylguanine (O
6-MeG)
a 428
O
6-benzylguanine (O
6-BnG)
a 0.18
O
6-(4-bromothenyl)guanine [O
6-(4-BTG)]
a 0.0034
IC50 values defined as the concentration of inactivator required to reduce the
activity of MGMT to 50%.
aIC50 values determined using same assay conditions as described in Materials
and Methods are taken from Ref. (37).
Figure 2. HPLC trace of crude DMT-ON O
6-BnG-containing 16mer ODN.
For HPLC conditions see Materials and Methods.
Figure 3. DoseresponsecurvesforinactivationofhumanMGMTby16merODNs.(a)O
6-(4-BTG)-andO
6-BnG-containingODNs;(b)O
6-MeG-containingODN;
(c) O
6-HOEtG-containing ODN.
Nucleic Acids Research, 2006, Vol. 34, No. 6 1889ODNs were two orders of magnitude more potent than the
corresponding O
6-MeG-containing ODN. The lower IC50 of
the O
6-(4-BTG)-containing ODN compared with the O
6-BnG-
containing ODN is in the same order as the IC50 values
displayed by the respective free bases.
CONCLUSIONS
In summary we have developed an efﬁcient and robust post-
DNA synthesis methodology applicable to the preparation
of a wide variety O
6-alkylguanine containing ODNs. The
availability of such ODNs will enable for the ﬁrst time a
more comprehensive assessment of the broader substrate
range of MGMT and related prokaryotic and eukaryotic alkyl-
transferases and alkyltransferase-related proteins (38,39).
Furthermore, the highly effective inactivation of MGMT by
an ODN containing O
6-(4-bromothenyl)guanine suggests that
such ODNs might have therapeutic applications if problems
of delivery can be addressed.
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Supplementary Data are available at NAR Online.
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